Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dispenzieri

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
Leukemia|January 30, 2004
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaS Kumar, T E Witzig, A Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Prognostic value of bone marrow angiogenesis in multiple myelomaS V Rajkumar, T Leong, P C Roche, et al.
Bone Marrow Transplantation|October 26, 2010
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalizationM A Gertz, D A Gastineau, M Q Lacy, et al.
Bone Marrow Transplantation|June 1, 2004
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapyS Kumar, M A Gertz, A Dispenzieri, et al.
Bone Marrow Transplantation|November 14, 2017
Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|August 6, 2013
Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCTS V Glavey, M A Gertz, A Dispenzieri, et al.
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Leukemia|January 30, 2004
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaS Kumar, T E Witzig, A Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Prognostic value of bone marrow angiogenesis in multiple myelomaS V Rajkumar, T Leong, P C Roche, et al.
Bone Marrow Transplantation|October 26, 2010
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalizationM A Gertz, D A Gastineau, M Q Lacy, et al.
Bone Marrow Transplantation|June 1, 2004
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapyS Kumar, M A Gertz, A Dispenzieri, et al.
Bone Marrow Transplantation|November 14, 2017
Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|August 6, 2013
Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCTS V Glavey, M A Gertz, A Dispenzieri, et al.
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Pageof 16